Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL... Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others. Show more
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase...
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the...
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported...
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management...
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -6.48 | -22.0633299285 | 29.37 | 30.66 | 21.24 | 116117 | 24.88799373 | CS |
4 | -2.95 | -11.4164086687 | 25.84 | 41.87 | 21.24 | 95594 | 29.96834482 | CS |
12 | 3.129 | 15.834218916 | 19.761 | 41.87 | 11.665 | 176337 | 19.89288288 | CS |
26 | 2.073 | 9.95820723447 | 20.817 | 41.87 | 11.665 | 452967 | 20.90853923 | CS |
52 | -1.305 | -5.39367637942 | 24.195 | 42.6 | 11.665 | 583250 | 23.56634433 | CS |
156 | -1.305 | -5.39367637942 | 24.195 | 42.6 | 11.665 | 583250 | 23.56634433 | CS |
260 | -1.305 | -5.39367637942 | 24.195 | 42.6 | 11.665 | 583250 | 23.56634433 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.